Loading asset research
Tango Therapeutics Inc.
TNGXNasdaq · USD · StocksQuote as of · Exchange session not verified$23.76
+1.68%
Today
TNGX
Loading 1D prices…
Market cap
$4B
Volume
2.3M
52w high
$34.3952w low
$6.38Company profile
Tango Therapeutics Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Boston, MA, United States
Employees
137
Fiscal year end
1231
CIK
1819133
Session & valuation
Open$23.72
Previous close$23.37
Day high$24.63
Day low$23.18
30-day avg. volume2.2M
Outstanding shares168.6M
Diluted EPS-$0.87
Latest annual period
P/E (trailing)-27.31
P/E (forward)-14.11
Price / book8.76
Beta1.12
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ELVNEnliven Therapeutics Inc. Common Stock | $4B | $0.00 | — | -$1.83 | -3.45% | Buy |
| INDVIndivior Pharmaceuticals Inc. Common Stock | $4.1B | $1.2B | +16.95% | $1.64 | -0.09% | Buy |
| MANEVeradermics Incorporated Common Stock | $4.1B | $0.00 | — | -$111.91 | +0.87% | Buy |
| TLXTelix Pharmaceuticals Limited American Depositary Shares | $3.8B | $803.8M | -0.89% | -$0.0211 | -5.21% | Buy |
| VKTXViking Therapeutics Inc. Common Stock | $3.7B | $0.00 | — | -$3.19 | -0.47% | Buy |